SOURCE: Smallcap-Investors

November 05, 2009 08:18 ET

Stocks on the Move: TPIV, INO, MBCI, CRXL

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Smallcap-Investors.com.

BOCA RATON, FL--(Marketwire - November 5, 2009) - TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell N.V (NASDAQ: CRXL).

Terms of the agreement allow TapImmune to use the proprietary PER.C6® cells in its development programs. The PER.C6® cell line is suited for the development and large-scale manufacturing of a multitude of biopharmaceuticals. In the use of recombinant vaccines using adenoviral vectors, PER.C6® cells do not generate replication competent adenoviruses, making it the state-of-the-art platform for the large-scale production of adenoviral vectors for clinical applications.

Inovio Biomedical Corporation (AMEX: INO) engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines rose almost 4% for the week.

Yesterday, MabCure N.V, a subsidiary of MabCure Inc. (OTCBB: MBCI), announced the signing of a research agreement with AZ Sint Lucas Hospital, Brugge, Belgium, to conduct preclinical research on its Monoclonal Antibodies (Mabs) against different cancers.

About Smallcap-Investors.com

Smallcap-Investors.com.com is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. Smallcap-Investors goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. Smallcap-Investors.com offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.Smallcap-Investors.com. An affiliate of Smallcap-Investors.com has been promised compensation by TapImmune Inc. for the dissemination of this Press Release.

Contact Information